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ABSTRACT
Tryptophan (Trp) metabolism is an important target in immuno-oncology as it represents a powerful
immunosuppressive mechanism hijacked by tumors for protection against immune destruction.
However, it remains unclear how tumor cells can proliferate while degrading the essential amino acid
Trp. Trp is incorporated into proteins after it is attached to its tRNA by tryptophanyl-tRNA synthestases.
As the tryptophanyl-tRNA synthestases compete for Trp with the Trp-catabolizing enzymes, the balance
between these enzymes will determine whether Trp is used for protein synthesis or is degraded. In
human cancers expression of the Trp-degrading enzymes indoleamine-2,3-dioxygenase-1 (IDO1) and
tryptophan-2,3-dioxygenase (TDO2) was positively associated with the expression of the tryptophanyl-
tRNA synthestase WARS. One mechanism underlying the association between IDO1 and WARS identified
in this study is their joint induction by IFNγ released from tumor-infiltrating T cells. Moreover, we show
here that IDO1- and TDO2-mediated Trp deprivation upregulates WARS expression by activating the
general control non-derepressible-2 (GCN2) kinase, leading to phosphorylation of the eukaryotic transla-
tion initiation factor 2α (eIF2α) and induction of activating transcription factor 4 (ATF4). Trp deprivation
induced cytoplasmic WARS expression but did not increase nuclear or extracellular WARS levels. GCN2
protected the cells against the effects of Trp starvation and enabled them to quickly make use of Trp for
proliferation once it was replenished. Computational modeling of Trp metabolism revealed that Trp
deficiency shifted Trp flux towards WARS and protein synthesis. Our data therefore suggest that the
upregulation of WARS via IFNγ and/or GCN2-peIF2α-ATF4 signaling protects Trp-degrading cancer cells
from excessive intracellular Trp depletion.
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Tryptophan (Trp) is the least abundant amino acid of the
standard genetic code. As an essential amino acid it cannot
be synthesized in humans but has to be taken up with the diet.1
In addition to serving as a building block for proteins, Trp
degradation to kynurenine (Kyn) and downstream metabolites
has evolved as a powerful immunoregulatory mechanism2,3. In
humans Trp degradation is catalyzed by three isoenzymes,
indoleamine-2,3-dioxygenase-1 and −2 (IDO1, 2) and trypto-
phan-2,3-dioxygenase (TDO2). While IDO1 and TDO2 are
recognized as major Trp degrading enzymes, the role of
IDO2 is less clear as it rather inefficiently catalyzes the conver-
sion of Trp to Kyn4. IDO1 is highly induced almost ubiqui-
tously by pro-inflammatory stimuli such as interferon gamma
(IFNγ)5, while TDO2 is constitutively expressed in the liver,
where it regulates systemic Trp levels3.
Trp degradation is thought to suppress immune cells in
two ways: Trp catabolites promote the differentiation of reg-
ulatory T cells (Treg)6–8 and induce apoptosis of T cells9. On
the other hand, Trp depletion has been implicated in the
proliferation arrest of CD8 + T cells10 by the accumulation
of uncharged transfer RNA (tRNA) and subsequent activation
of the general control non-derepressible-2 (GCN2) kinase
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pathway11,12, while Gcn2 in T cells has recently been shown to
be dispensable for the suppression of antitumor immune
responses in experimental melanomas13.
Trp degrading enzymes are expressed in many cancers.
IDO1, for instance, is expressed in about 58% of human
cancers14, and also TDO2 is present in multiple cancer entities
including melanoma, ovarian carcinoma, hepatic carcinoma,
non-small cell lung cancer, renal cell carcinoma, bladder can-
cer, breast cancer and glioblastoma15–17. As the degradation of
the essential amino acid Trp is a key mechanism for immune
evasion in many tumors, the question arises how the tumor
cells concomitantly sustain their capacity for protein synthesis
and excessive proliferation. The cytoplasmic tryptophanyl-
tRNA synthetase (TrpRS) WARS and the mitochondrial
TrpRS WARS2 attach Trp to their tRNAs, which is required
for the incorporation of Trp into proteins. We hypothesized
that increased expression of TrpRS may enable the cancer cells
to incorporate Trp into their proteins despite low Trp levels.
We therefore investigated the regulation of the TrpRS WARS
and WARS2 upon Trp degradation and their balance with the
Trp catabolizing enzymes.
Results
IDO1 and WARS are jointly induced by IFNγ produced by
tumor infiltrating T cells in breast cancer, colon cancer
and B cell lymphoma
To investigate if a relationship exists between the expression
of IDO1 and the two TrpRS WARS and WARS2 we analyzed
gene expression data of breast cancer, colon carcinoma and B
cell lymphoma, as these neoplasms have been reported to
express IDO118. We observed a strong positive correlation
between IDO1 and WARS but not WARS2 (Figure 1A). T
cell-specific genes such as CD2 and CD3D also strongly cor-
related withWARS and IDO1, suggesting that their expression
is induced by factors released by T cells (Figure 1B, Fig. S1A,
and B). Furthermore, IDO1 and WARS positively correlated
with the expression of IFNG as well as the IFNγ-induced
genes STAT1 and IRF119, suggesting that IDO1 and WARS
induction is mediated through IFNγ (Figure 1C, Fig. S1 C
and D).
Indeed, supernatants of activated primary human T cells
induced IDO1 and WARS mRNA and protein expression in
breast cancer cells, while they did not increase WARS2 levels
(Figure 1D). The induction of IDO1 and WARS by the super-
natants of activated primary human T cells was abrogated by
addition of an IFNγ blocking antibody (Figure 1D), confirm-
ing that IFNγ is the T cell factor inducing IDO1 and WARS.
In keeping with this, also recombinant IFNγ induced IDO1
and WARS, but not WARS2 expression (Figure 1E).
TDO2 and IDO1 activity upregulate WARS expression
As TDO2 also degrades Trp in cancer cells, we next analyzed
whether WARS or WARS2 gene expression correlated with
TDO2. To explore if a relationship exists between the expres-
sion of TDO2 and the two TrpRS, we selected glioma, breast
cancer, and ovarian carcinoma as cancer entities, which are
known to express high TDO2 levels15-17. Indeed TDO2
expression correlated with WARS but not WARS2
(Figure 2A and B), although the correlations were less strong
than for IDO1 (Figure 1A). We next investigated whether the
correlation between WARS and TDO2 is also mediated by
joint induction through IFNγ. However, our data did not
support this hypothesis, as recombinant IFNγ failed to induce
TDO2 in two distinct glioblastoma cell lines (Figure 2C). We
therefore tested whether WARS induction is mediated by
TDO2 itself. TDO2 overexpression in LN229 glioblastoma
cells lacking endogenous TDO2 (Figure 2D) decreased Trp
and increased Kyn levels (Figure 2E), confirming that the
overexpressed TDO2 efficiently degraded Trp. In line with
our hypothesis also WARS expression was induced by TDO2
overexpression (Figure 2F), suggesting a causal relationship
between TDO2 expression and WARS induction. In contrast,
WARS2 was reduced in TDO2 overexpressing cells
(Figure 2G).
As TDO2 degrades Trp, it would be likely that Trp degradation
is responsible for WARS induction. To corroborate this we over-
expressed IDO1 (Figure 2H), the other enzyme that degrades Trp
to Kyn (Figure 2I). Similarly to TDO2 also IDO1 overexpression
induced WARS (Figure 2J) but not WARS2 (Figure 2K). Taken
together our data suggest that both IDO1 and TDO2 act upstream
of WARS by inducing its expression.
Trp depletion upregulates WARS expression
IDO1 and TDO2 both degrade Trp to Kyn, leading to Trp depri-
vation and accumulation of Trpmetabolites3. Therefore, the ques-
tion arises whether the accumulation of Trp metabolites or the
depletion of Trp induces WARS. To this end we cultured A172
glioblastoma cells, which exhibit constitutive TDO2 activity16,17,
for 5 days in complete medium without or with additional Trp
supplementation. Trp supplementation, a condition that promotes
the accumulation of Trp metabolites, reduced WARS expression
(Figure 3A), while not affectingWARS2 (Figure 3B). Conversely,
Trp starvation induced WARS mRNA (Figure 3C) in cell lines
with high (A172) and medium (LN18) TDO2 expression, high
IDO1 expression (SKOV3) as well as in cells that do not express
any Trp-degrading enzymes (LN229)16,20. The increase in WARS
mRNA upon Trp starvation also translated into increased WARS
protein levels as assessed in LN229 glioblastoma cells. (Figure 3D).
Similar to IDO1 overexpression (Figure 2K), also Trp starvation
did not alter WARS2 levels (Figure 3E). Based on these results we
conclude that the degradation of Trp induces WARS not through
the accumulation of Trp metabolites but by depleting Trp.
In addition to attaching Trp to its specific tRNA, which
occurs mainly in the cytoplasm, WARS is involved in
cellular signaling processes in the nucleus or in the extra-
cellular space21-24. To investigate if Trp starvation affects
WARS expression in specific cellular locations, we ana-
lyzed WARS protein expression in cytoplasmic and
nuclear cell fractions (Figure 3F) as well as in cell super-
natants (Figure 3G). In the cytoplasmic fraction WARS
protein expression was enhanced in response to Trp star-
vation (Figure 3F). In contrast, in the nuclear fraction
WARS expression was not altered by Trp starvation
(Figure 3F). In cell supernatants of LN229 and A172
e1486353-2 I. ADAM ET AL.
Figure 1. IDO1 and WARS correlate with each other and are both associated with the expression of T cell markers and with IFNγ signaling.
(A) Left: Correlation between IDO1 and WARS expression in breast cancer, colon cancer and B-cell lymphoma. Right: IDO1 and WARS2 expression in breast cancer,
colon cancer and B-cell lymphoma do not correlate with each other (n = 124 for breast cancer, n = 355 for colon cancer, n = 215 for lymphoma, Spearman’s rank
correlation). (B) WARS (red) and IDO1 (blue) expression are significantly correlated with the expression of the T cell markers CD3D and CD2, and (C) with the
expression of IFNG, STAT1 and IRF1 in breast cancer (n = 124, Spearman’s rank correlation). (D) IDO1, WARS and WARS2 mRNA levels measured by qRT-PCR and IDO1
and WARS protein measured by Western blot after treatment of the human breast cancer cell lines MCF7, BT-474 and MDA-MB-231 with supernatants of activated
CD4 + T cells in the absence and presence of an IFNγ blocking antibody. (E) IDO1, WARS and WARS2 mRNA levels measured by qRT-PCR and IDO1 and WARS protein
measured by Western blot after treatment of MCF7 cells with 1000 U/ml recombinant IFNγ. All data are expressed as mean ± s.e.m. Statistical significance is assumed
at P < 0.05 (*P < 0.05, **P < 0.01, ***P <0.001).
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Figure 2. TDO2 and IDO1 activity upregulate WARS expression.
(A) Correlation between TDO2 and WARS expression in human glioma, breast cancer, and ovarian cancer. (B) TDO2 and WARS2 expression in glioma, breast cancer, and
ovarian cancer do not correlate with each other (n = 50 for glioma, n = 124 for breast cancer, n = 90 for ovarian cancer, Spearman’s rank correlation). (C) Treatment of A172
and LN18 glioblastoma cells with 100 U/ml or 1000 U/ml IFNγ did not alter TDO2mRNA expressionmeasured by qRT-PCR. (D) TDO2mRNA expression in LN229 glioblastoma
cells after overexpression of TDO2. (E) HPLC chromatograms showing Trp (top) and Kyn (bottom) measured in the supernatants of control-transduced (blue) and TDO2-
overexpressing (red) LN229 glioblastoma cells. (F) WARS mRNA expression measured by qRT-PCR in control-transduced and TDO2-overexpressing LN229 cells. (G) WARS2
mRNA expression measured by qRT-PCR in control-transduced and TDO2-overexpressing LN229 cells. (H) IDO1 mRNA expression in HEK 293 cells after overexpression of
IDO1. (I) HPLC chromatograms showing Trp (top) and Kyn (bottom) measured in the supernatants of control-transfected (blue) and IDO1-overexpressing (red) HEK 293 cells.
(J) WARS mRNA expression measured by qRT-PCR in control-transfected and IDO1-overexpressing HEK 293 cells. (K) WARS2 mRNA expression measured by qRT-PCR in
control-transfected and IDO1-overexpressing HEK 293 cells. All data are expressed as mean ± s.e.m. Statistical significance is assumed at P < 0.05 (*P < 0.05, **P < 0.01,
***P <0.001).
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glioblastoma cells WARS protein expression was reduced
in response to 48 h of Trp starvation (Figure 3G). Taken
together, our results suggest that Trp starvation increases
cytoplasmic WARS protein levels but not nuclear or extra-
cellular WARS expression.
GCN2-peIF2α-ATF4 signaling mediates the upregulation
of WARS in response to trp depletion
As Trp depletion mediates WARS induction and is known to
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Figure 3. Trp depletion upregulates WARS expression.
(A) WARS mRNA expression measured by qRT-PCR in A172 glioblastoma cells, which exhibit constitutive TDO2 activity, cultured for 120 h in normal DMEM or with
additional supplementation of 78 µM Trp after 72 h. (B) WARS2 mRNA expression measured by qRT-PCR in A172 glioblastoma cells under the conditions described in
(A). (C) WARS mRNA expression measured by qRT-PCR in glioblastoma (A172, LN18, LN229) and ovarian carcinoma cells (SKOV-3) after 24 h of cultivation in medium
containing 78 µM versus no Trp. (D) WARS protein levels in LN229 glioblastoma cells detected by Western blot after 48 h or 72 h of cultivation in medium containing
78 µM or no Trp. GAPDH served as loading control (E) WARS2 mRNA expression measured by qRT-PCR was not altered by the conditions described in (C). (F) WARS
protein levels in the cytoplasmic or nuclear fraction of LN229 glioblastoma cells detected by Western blot after 48 h of cultivation in medium containing 78 µM or no
Trp. GAPDH served as loading control for the cytoplasmic fraction, lamin A/C as loading control for the nuclear fraction. (G) WARS protein concentrations measured
by ELISA in the supernatants of LN229 and A172 glioblastoma cells cultured for 48 h in the presence or absence of Trp. All data are expressed as mean ± s.e.m.
Statistical significance is assumed at P < 0.05 (*P < 0.05, **P < 0.01, ***P <0.001).
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upregulation of WARS. For this purpose, GCN2 was knocked
down in LN229 glioblastoma cells that were cultured with or
without Trp (Figure 4A). GCN2 knockdown inhibited WARS
induction by Trp deprivation on both mRNA (Figure 4B) and
protein (Figure 4C) level. However, as expected it did not
affect WARS2 (Figure 4D). Similar results were obtained in
Gcn2 knockout mouse embryonic fibroblasts (MEFs)
(Figure 4E-H). These results suggest that GCN2 mediates
the induction of WARS in response to Trp deprivation.
GCN2 is activated by sensing of uncharged tRNA and
therefore should not be specific for Trp starvation25,26. In
keeping with this, depletion of any essential amino acid
resulted in an induction of WARS mRNA, albeit to different
levels with depletion of Trp, valine and phenylalanine being
the strongest inducers of WARS (Figure 4I).
To further elucidate the downstream effects of GCN2 activa-
tion we next set out to establish whether Trp starvation leads to
phosphorylation of the translation initiation factor eIF2α asGCN2
is known to inhibit eIF2α by phosphorylation27. Indeed, Trp
starvation enhanced eIF2α phosphorylation at serine 51
(Figure 4J). To investigate whether eIF2α phosphorylation is
required for WARS induction by Trp starvation, we used MEFs
that express either wildtype eIF2α (SS) or a version in which serine
51 ismutated to an alanine (AA) and cannot be phosphorylated by
Gcn2 (Figure 4K). Trp-starved AA-MEFs showed reduced Wars
expression, as compared to SS-MEFs, indicating that eIF2α phos-
phorylation is required for the induction of WARS upon Trp
starvation (Figure 4K).
eIF2α phosphorylation enhances translation28 and tran-
scription of ATF429. In line, ATF4 protein (Figure 4L) and
ATF4 mRNA (Fig. S2) levels increased upon Trp starvation.
Importantly, knockdown of ATF4 in LN229 cells (Fig. S2)
impaired WARS induction by Trp starvation (Figure 4M).
Hence, ATF4 mediates enhanced WARS expression in Trp-
deprived cells. In agreement, WARS and ATF4 levels posi-
tively correlated in human malignant gliomas (Figure 4N).
As ATF4 has been reported to regulate the transcription of
many tRNA synthetases 25,30–32, we next compared the expression
of WARS to that of all other tRNA synthetases in U87-MG
glioblastoma cells that were Trp starved for 24 h. Trp starvation
most strongly induced WARS mRNA expression (2,6 fold;
Figure 4O). In addition, 7 other tRNA synthetases (glycyl-tRNA
synthetase, GARS; cysteinyl-tRNA synthetase, CARS; alanyl-
tRNA synthetase, AARS; methionyl-tRNA synthetase, MARS;
seryl-tRNA synthetase, SARS; tyrosyl-tRNA synthetase, YARS
and glutamyl-prolyl-tRNA synthetase, EPRS) were upregulated
more than 1.5 fold. All of these tRNA synthetases are expressed
in the cytoplasm, suggesting that – as already observed for WARS
and WARS2 – the cytoplasmic and not the mitochondrial tRNA
synthetases are primarily regulated though amino acid limitation.
Taken together, our results indicate that Trp starvation upre-
gulatesWARS expression through the GCN2-peIF2a-ATF4 axis.
Gcn2 protects cells against the effects of Trp shortage
and enables an optimal utilization of Trp when it is
replenished
Next, we aimed to assess the effect of the observed WARS
upregulation on the proliferation and survival of Trp-starved
cancer cells. As we wanted to investigate the impact of the
upregulation of WARS and not the general effect of WARS on
cell proliferation and survival, we did not knockdown WARS,
but analyzed how GCN2, which is required for WARS upregu-
lation, modulates the cellular response to Trp starvation and
replenishment. We reasoned that if the upregulation of WARS
is protective against Trp depletion then GCN2 should also
protect cells against Trp depletion. To test if GCN2 indeed
confers an advantage on cells coping with Trp shortage, we
analyzed the proliferation of wt and Gcn2 -/- MEFs under
Trp-free conditions and in response to Trp replenishment
after 24 h of Trp starvation. At 24 h of Trp starvation wt and
Gcn2 -/- MEFs showed similar proliferation (Figure 5A).
However, after that, the wt MEFs slowly proliferated further,
whereas the Gcn2 -/- MEFs showed a strong decrease in pro-
liferation (Figure 5A), indicated by a negative slope (1/h)
(Figure 5B). Re-addition of Trp increased the proliferation of
both wt and Gcn2 -/- MEFs, however, proliferation of Gcn2 -/-
MEFs only recovered to levels similar to those of Trp-deprived
wt cells (Figure 5A and B). Therefore, GCN2 seems to protect
cells against the effects of Trp starvation and enables them to
quickly make use of Trp when it is replenished.
Trp shortage channels trp towards WARS and protein
synthesis
Our results presented so far demonstrate that IDO1 and
TDO2 act upstream of WARS (Figure 6A). As IDO1 and
WARS are induced in parallel by IFNγ (Figure 6A), IFNγ
and Trp deprivation might have additive effects on WARS
expression. To test this, we stimulated LN18 glioblastoma cells
with IFNγ, deprived them of Trp or used a combination of
both (Figure 6B). In support of our hypothesis, the combina-
tion of IFNγ with Trp deprivation enhanced WARS mRNA
expression more strongly than either treatment alone
(Figure 6B).
As WARS is necessary for the incorporation of Trp into
proteins, we propose that WARS induction in response to Trp
depletion channels Trp into protein synthesis (Figure 6A). In
this scenario WARS and the Trp-metabolizing enzymes com-
pete for Trp and the balance of these enzymes will determine
whether Trp is used for protein synthesis or is converted to
other metabolites. Computational modelling provides a means
to quantitatively analyze metabolite usage by different path-
ways. To obtain an overview of the fate of Trp under condi-
tions of Trp deficiency, we integrated gene expression data of
U87-MG glioblastoma cells under Trp sufficiency or depriva-
tion, into an extended version of a previously published
mathematical model of Trp metabolism that is based on
existing kinetic data for the enzymatic conversions and
transporters33. In line with the previously described upregula-
tion of amino acid transporters in response to Trp
deprivation34,35, the model predicted increased flux of Trp
into the cells (Figure 6C). Kyn is transported by some of the
same antiporters as Trp.36 Therefore, the increase of these
antiporters also enhanced flux of Kyn out of the cells resulting
in reduced flux down the Kyn pathway (Figure 6C). Most
prominently, Trp deficiency shifted Trp flux towards WARS
and thus protein synthesis (Figure 6C), supporting our
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Figure 4. GCN2-peIF2a-ATF4 signaling mediates the upregulation of WARS in response to Trp depletion.
(A) GCN2 mRNA expression measured by qRT-PCR in LN229 cells after knockdown of GCN2 by siRNA cultured in the absence and presence of 78 µM Trp for 24 h. (B)
WARS mRNA expression measured by qRT-PCR and (C) WARS and GCN2 protein expression detected by Western blot under the conditions described in (A). GAPDH
served as loading control. (D) WARS2 mRNA expression measured by qRT-PCR under the conditions described in (A). (E) Gcn2 mRNA expression in wildtype (wt) and
Gcn2 −/- MEFs cultured in the absence and presence of 78 µM Trp for 24 h. (F) Wars mRNA expression measured by qRT-PCR and (G) WARS and GCN2 protein
expression detected by Western blot under the conditions described in (E). Tubulin served as loading control. (H) Wars2 mRNA expression measured by qRT-PCR
under the conditions described in (E). (I) WARS mRNA expression measured by qRT-PCR in full DMEM medium (DMEM), in amino acid-free DMEM supplemented with
all amino acids (+ all AA) and in amino acid-free DMEM supplemented with all but each of the essential amino acids (EAA). (J) peIF2a and eIF2a detected by Western
blot in LN229 cells cultured in the presence (+) or absence (-) of 78 µM Trp for 24 h. (K) Wars mRNA expression measured by qRT-PCR in MEFs that express wildtype
Eif2a (SS) or an Eif2a version, in which serine 51 is mutated to an alanine and cannot be phosphorylated by Gcn2 (AA). MEFs were cultured for 24 h in the presence or
absence of 78 µM Trp. (L) ATF4 protein detected by Western blot in LN229 cells cultured for 24 h in the presence or absence of 78 µM Trp. GAPDH served as loading
control. (M) WARS mRNA expression measured by qRT-PCR in LN229 cells after knockdown of ATF4 by siRNA cultured in the absence and presence of 78 µM Trp for
24 h. (N) Correlation between ATF4 and WARS expression in human glioma (n = 50, Spearman’s rank correlation). All data are expressed as mean ± s.e.m. Statistical
significance is assumed at P < 0.05 (*P < 0.05, **P < 0.01, ***P <0.001). (O) Lolli-plot showing the absolute fold changes of all the tRNA synthetases in a microarray of
U87-MG cells upon 24 h of Trp starvation.
ONCOIMMUNOLOGY e1486353-7
hypothesis, that WARS upregulation enables the cells to
maintain protein synthesis despite low levels of Trp.
Discussion
We show here that in addition to being induced concomi-
tantly with IDO1 through IFNγ signaling5,37,38,(Figure 1,
WARS is directly upregulated in response to Trp shortage
caused by IDO1 or TDO2 activity (Figure 2 and 3). Trp
shortage mediates WARS upregulation by signaling via the
GCN2-peIF2a-ATF4 axis (Figure 4), as low levels of Trp result
in the accumulation of uncharged tRNAs, which activate the
stress kinase GCN210. GCN2 then phosphorylates its sub-
strate, eIF2a leading to reduced global protein synthesis, but
increased translation of specific mRNAs such as ATF427,28.
Our results reveal that expression of GCN2 and ATF4 as well
as phosphorylation of eIF2a are each required for the induc-
tion of WARS upon Trp degradation (Figure 4). ATF4 upre-
gulation then most likely induces WARS expression via direct
promoter binding30.
In contrast toWARS, mitochondrial WARS2 did not correlate
with IDO1 or TDO2 (Figure 1A; Figure2B) and was regulated
neither by IFNγ (Figure 1E)39 nor by GCN2-peIF2a-ATF4 signal-
ing (Figure 4D and H). Both WARS and WARS2 belong to the
class I aminoacyl-tRNA synthetases, which contain a characteristic
Rossman fold catalytic domain39. However,WARS2 only aligns to
the carboxyl-terminal part of WARS and thus the two enzymes
only share 11% sequence identity39. The two TrpRS bind tRNAs
with different anticodons. WARS2 binds mitochondrial tRNATrp
with the anticodonUCA,which codes for Trp in themitochondria
of humans40, while WARS binds cytoplasmic tRNATrp, which
contains the standard anticodon CCA. Little is known about free
Trp concentrations in mitochondria and it is therefore not clear
how mitochondrial Trp concentrations are affected by Trp deple-
tion. Our results reveal that Trp starvation, which most strongly
induces WARS, generally appears to upregulate the expression of
cytoplasmic rather than mitochondrial tRNA synthetases
(Figure 4O).
In addition to its role in aminoacylation, WARS, like many
other tRNA synthethases41-43, has been implicated in cellular
signaling. A truncated version of WARS is secreted in
response to IFNγ and elicits angiostatic effects23 through
inhibition of endothelial cell-cell junctions24. Upon infection,
monocytes secrete full-length WARS, which induces phago-
cytosis and chemokine production in macrophages21. We
therefore tested if the upregulation of WARS in response to
Trp shortage also increases extracellular WARS protein levels.
However, Trp starvation reduced WARS protein levels in the
cell supernatants (Figure 3G), indicating that less WARS is
secreted under Trp starvation conditions. Upon IFNγ stimu-
lation, WARS has been shown to translocate into the nucleus,
bridge DNA-dependent protein kinase (DNA-PKcs) to poly
(ADP-ribose) polymerase 1 (PARP-1), which stimulates
PARylation of DNA-PKcs, in turn enhancing the kinase activ-
ity of DNA-PKcs for p53 phosphorylation and activation22.
Interestingly, an empty Trp-AMP pocket is necessary for the
nuclear function of WARS22, which is likely to be present in
conditions of Trp depletion. We therefore originally hypothe-
sized that WARS induction through GCN2-peIF2a-ATF4 sig-
naling may contribute to p53 activation observed under
nutritional stress44. However, we found that the upregulation
of WARS expression under conditions of Trp shortage, pri-
marily affected cytoplasmic WARS, while the expression of
WARS in the nucleus did not change (Figure 3F). Hence, Trp
starvation appears to primarily modulate WARS levels
involved in protein synthesis.
As Trp is the least abundant of the standard proteino-
genic amino acids, it is assumed to play a rate-limiting
role during protein synthesis. Diverse mechanisms includ-
ing the suppression of mTOR signalling and the induction
of autophagy have been reported to adapt cells to Trp
starvation45,46. Furthermore, activation of GCN2-peIF2α-
ATF4 signaling by Trp starvation was shown to mediate
the upregulation of Trp transporters35, suggesting that the
GCN2-peIF2α-ATF4 axis coordinates multiple adaptations
to Trp starvation. Indeed, GCN2 enabled cells to slowly
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Figure 5. Gcn2 protects cells against the effects of Trp shortage and enables them to optimally make use of Trp when it is replenished.
(A) MEFs were cultured in the presence or absence of 78 µM Trp following a 24 h period of Trp starvation. Cell proliferation of wt and Gcn2-/- MEFs was monitored
by the xCELLigence RTCA system. Displayed are the values measured every 4 h over a 3-day period. (B) Slopes of the proliferation curves depicted in (A). Data are
expressed as mean ± s.e.m. Statistical significance is assumed at P < 0.05 (*P < 0.05, **P < 0.01, ***P <0.001).
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Figure 6. Trp shortage channels Trp towards WARS and protein synthesis.
(A) Cartoon depicting the mechanisms underlying the regulation of WARS by Trp-degrading enzymes. (B) WARS mRNA expression measured by qRT-PCR of LN18
glioblastoma cells treated with 0, 100 and 1000 U/ml of IFNγ in the presence and absence of 78 µM Trp. (C) Scheme depicting the most prominent flux changes in Trp
metabolism upon Trp depletion. Fluxes were calculated by integration of microarray data from U87-MG glioblastoma cells into a computational model of Trp
metabolism. Bar heights represent relative change in percentage between cells growing in normal media and cells growing without Trp. All data are expressed as
mean ± s.e.m.
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proliferate despite Trp depletion and to rapidly start pro-
liferating upon Trp replenishment (Figure 5). Most likely
the regulation of both Trp transporters and WARS act
downstream of GCN2 to adapt the cells to low Trp con-
ditions and to enable them to optimally make use of Trp
once it is available again.
Interestingly, also IFNγ has been reported to induce a
Trp-selective transporter47 and IFNγ-induced WARS was
recently shown to augment intracellular Trp levels48. The
redundancy of IFNγ (which leads to Trp degradation via
IDO1 induction), and GCN2-peIF2α-ATF4 signaling
(which is activated upon low Trp levels), in inducing
WARS and Trp transporters may hint to the importance of
securing sufficient intracellular Trp levels. Most likely, IFNγ
will already induce WARS and Trp transporters before Trp
levels low enough to activate GCN2 are reached. Of note,
IFNγ-induced WARS mRNA was further increased in
response to Trp starvation (Figure 6B), suggesting that a
more pronounced upregulation of WARS is possible if Trp
levels continue to decline.
Although several studies have shown that amino acid transpor-
ters are upregulated in response to Trp deprivation to increase Trp
import34,35,47,49, it is unclear whether this intracellular increase in
Trp leads to further degradation by Trp catabolizing enzymes or
can be used for protein synthesis. By applying computational
modelling of Trp usage in different pathways, we confirmed the
upregulation of Trp transporters35, which resulted in enhanced
influx of Trp into the cells but also increased efflux of Kyn out of
the cells (Figure 6C). However, most strikingly, Trp shortage
channeled Trp towards WARS (Figure 6C).
In conclusion, we show here that in tumor cells, Trp depletion
mediated by the expression of IDO1 and/or TDO2 upregulates
WARS via GCN2-peIF2a-ATF4 signaling, which shifts Trp usage
towards protein synthesis. The GCN2-dependent upregulation of
WARS and Trp transporters enables cells to adapt to Trp shortage
and to make optimal use of Trp once it is replenished. Hence, this
study sheds light on an important compensatory mechanism
allowing tumor cells to grow despite degrading an essential
amino acid.
Methods
Analysis of expression data
For correlation analyses, data was downloaded from the R2:
Genomic Analysis and Visualization Platform (http://hgserver1.
amc.nl) and Gene Expression Omnibus (GEO). The following
datasets were used: “Tumor Glioma Kawaguchi” (GSE43378),
“Tumor Breast Chin” (GSE69031)50, “Tumor Colon Sieber-
Smith“ (GSE14333 + GSE17538 minus identical samples),
“Tumor Lymphoma Hummel”51, “Tumor Ovarian Anglesio”52.
Probes considered for analyses were: ATF4: 200779_at, CD2:
205831_at, CD3D: 213539_at, IDO1: 210029_at, IFNG:
210354_at, IRF1: 202531_at, TDO2: 205943_at, WARS:
200629_at. As for WARS2 the same probes were not available
for all datasets, 222734_at was employed for “Tumor Ovarian
Anglesio”, “Tumor Glioma Kawaguchi” and “Tumor Colon
Sieber-Smith”, while 218766_s_at was used for “Tumor Breast
Chin” and “Tumor Lymphoma Hummel”.
Cell culture
Human cancer cell lines were obtained from ATCC. MEFs
eIF2αS51A/S51A (AA-MEFs) and the corresponding controls,
MEFs eIF2αS51/S (SS-MEFs)53 were obtained from the R.
Kaufman laboratory. Cells were cultivated in DMEM
(Gibco) supplemented with 10% FCS (Gibco), 100 U/ml
penicillin and 100 µg/ml streptomycin (Gibco).
For essential amino acid depletion, cells were cultured for
24 h in DMEMwithout amino acids (Thermo Fisher Scientific)
supplemented with all amino acids at the concentrations of
regular DMEM but lacking each essential amino acid. Regular
DMEM (Gibco) and DMEM without amino acids (Thermo
Fisher Scientific) supplemented with all amino acids at the
concentrations of regular DMEM were used as controls.
L-Arginine, L-Glutamine, L-Histidine, L-Serine, L-Threonine,
L-Valine and L-Isoleucine were all from Genaxxon,
L-Tryptophan, L-Cysteine, L-Leucine and L-Lysine were all
from Sigma-Aldrich, L-Glycine, L-Phenylalanine and
L-Tyrosine were from Carl Roth, and L-Methionine was from
Usbiologicals. All media were supplemented with 10% dialyzed
FCS (Gibco).
Drug and cytokine treatment
Cells were treated with recombinant human IFNγ (#14–
8319-80, eBiosciences) at concentrations of 100 and
1000 U/ml for 8 and 24 h. For inhibition of IFNγ signaling
an anti IFNγ antibody (#554,698, BD Bioscience) was
applied at 5µg/ml.
Preparation of T cell supernatants
Peripheral blood mononuclear cells were prepared from
heparinized venous blood of healthy donors by density-gra-
dient centrifugation. T helper (Th) cells were separated using
a CD4+ T cell isolation kit II (Miltenyi Biotec GmbH)
according to the manufacturer’s instructions (purity ≥97%
CD4+ cells). Th cells were cultured in RPMI 1640 medium
(Thermo Fisher Scientific) containing 10% FCS in the pre-
sence of 5 μg/ml phytohemagglutinin (Sigma-Aldrich) and
20 ng/ml rhIL-2 (Novartis) for 4 days. Activated T cell
supernatants were harvested, centrifuged and stored
at −80°C.
RNA isolation and quantitative (q)RT-PCR
Total RNA was isolated using the Qiagen RNAeasy Mini Kit
(Qiagen) following the manufacturer’s instructions. One micro-
gram RNA was reversed transcribed to cDNA using the High
Capacity cDNA reverse transcriptase kit (Applied Biosystems).
(q)RT-PCR was carried out in quadruplicates with the SYBR
Select Master Mix (Thermo Fisher Scientific) with a
StepOnePlus real-time PCR system (Applied Biosystems).
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GAPDH was used for normalization. qRT-PCR primers were
designed using Primer Blast (NCBI) and were separated by at
least one intron on the genomic DNA.
Primers sequences:
Human
ATF4 forward : 5’- CCTATAAAGGCTTGCGGCCA -3’
reverse: 5’- CACTGCTGCTGGATTTCGTG -3’
GAPDH forward: 5’-CTCTCTGCTCCTCCTGTTCGAC-3’
reverse: 5’-TGAGCGATGTGGCTCGGCT-3’
GCN2 forward : 5’- CGACTTCAGACCTCCCTTGC -3’
reverse: 5’- GGTATCTTTGCTTTGGCAGGC -3’
IDO1 forward : 5’-GATGTCCGTAAGGTCTTGCC -3’
reverse: 5’-TCCAGTCTCCATCACGAAAT-3’
TDO2 forward: 5’- CAAATCCTCTGGGAGTTGGA - 3’
reverse: 5’- GTCCAAGGCTGTCATCGTCT - 3’
WARS forward: 5’- ATTCTCAAGAGGGTTTCATT - 3’
reverse: 5’- CCAGGTTGTGGAAGACACT - 3’
WARS2 forward: 5’- CTGCACTCAATGCGGAAA - 3’
reverse: 5’- GGATTCCTGTAGGTTGAATG - 3’
Murine
Gapdh forward: 5’- GCCTTCCGTGTTCCTACCC -3’
reverse: 5’- CAGTGGGCCCTCAGATGC -3’
Gcn2 forward: 5’- GCTGCGTTCTTCAGTGAGACAC - 3’
reverse: 5’- GCTTGTTTTGCACCTTGATGAC - 3’
Wars forward: 5’- ACCGGAAGTTATTCCAGCCG - 3’
reverse: 5’- TCACGAGCTCCCCTTGAGTA - 3’
Wars2 forward: 5’- GGCCAATTGCCTGTTTAGCTC - 3’
reverse: 5’- GAATGCACTGACCCTGTTCC - 3’
Protein isolation and western blotting
Cells were lysed in ice-cold RIPA lysis buffer (1% IGEPAL/
NP40, 12 mM sodium-deoxycholate, 3.5 mM SDS) supple-
mented with a protease and phosphatase inhibitor (Roche/
Sigma-Aldrich) to extract total protein. Nuclear and cyto-
plasmic fractions were prepared using the NE-PER Nuclear
Cytoplasmic Extraction Reagent kit (Pierce) according to
the manufacturer’s instruction. Protein concentrations
were determined by Bradford Protein Assay (BioRad)
according to the manufacturer’s recommendations. 10 to
20 µg of protein were separated by 10–12% SDS-PAGE.
Proteins were transferred onto 0.2 µm nitrocellulose mem-
branes, blocked with 5% BSA for 1 h, and stained with the
corresponding primary antibodies overnight. Primary anti-
bodies: rabbit anti-human IDO1 (#AG-25A-0029-C100,
Adipogene AG), mouse anti-human GAPDH (#39–8600,
Thermo Fisher Scientific), mouse anti-human ß-Actin
(#MA5-15,739, Thermo Fisher Scientific), mouse anti-
Lamin A/C (#MA3-1000, Thermo Fisher Scientific), rabbit
anti-human WARS (#GTX62563, Gene Tex, Inc.), rabbit
anti-human WARS (#PA5-29,849, Thermo Fisher
Scientific) rabbit anti-human Tubulin (#ab108629, Abcam
plc.), goat anti-human ATF4 (#sc7583, Santa Cruz
Biotechnology, Inc.), rabbit anti-human GCN2 (#PA5-
17523# Pierce Protein Biology), were diluted 1:1000 in
blocking solution.
For detection, membranes were stained with HRP-conju-
gated secondary antibodies (α-rabbit:#GENA9340-1M, GE
Healthcare Europe GmbH; α-goat: #SC-2020, Santa Cruz
Biotechnology; α-mouse: #GENXA931, GE Healthcare)
diluted 1:5000 for 1 h at room temperature (RT). Signals
were detected using either Pierce® ECL Western Blotting
Substrate or SuperSignal® West Femto Maximum Sensitivity
Substrate (both Thermo Scientific). Images were captured on
the BioRad ChemiDoc MP system with Image Lab 5.1
software.
ELISA of cell supernatants
WARS protein levels were measured in FCS-free cell super-
natants of A172 and LN229 glioblastoma cells cultured in the
presence or absence of Trp for 48 h using a commercially
available ELISA kit (Elabscience) according to the manufac-
turer’s protocol.
Generation of TDO2 overexpression cell lines
A TDO2 cDNA clone flanked by Gateway compatible recom-
bination sites was obtained from MyBiosource. The cDNA
clone was recombined into the pLX301 vector (Addgene plas-
mid #25895), using the Gateway® LR Clonase Enzyme mix
(Thermo Fisher Scientific) according to the manufacturer’s
protocol. The pLX301-TDO2 expression vector or the empty
control pLX301 vector was co-transfected into HEK293T cells
using lentiviral packaging plasmids. The resulting lentiviral
supernatants were used to infect LN229 cells. Cells with stable
integration of the expression vectors were selected and main-
tained in complete DMEM containing 1µg/ml puromycin.
The stable overexpression of TDO2 was confirmed by qRT-
PCR, while the functional activity of the overexpressed pro-
tein was verified by enhanced Kyn and reduced Trp levels in
the supernatants of the TDO2 overexpressing cells, as mea-
sured by HPLC.
Overexpression of IDO1 in HEK 293 cells
Starting from the pDEST26 vector (Invitrogen, Thermo Fisher
Scientific), the 6xHis-tag was removed by site-directed muta-
genesis PCR to derive pDEST. Subsequently, a single
C-terminal Flag-tag (Flag-C) was introduced into pDEST. The
full-length cDNA sequence of IDO1 was cloned into pDEST-
Flag-C via Gateway® cloning resulting in pDEST-IDO1-FLAG-
C. HEK293 cells were seeded into 6 well plates, cultured for
24 h and transfected with 2 µg of pDEST-IDO1-FLAG-C or
empty control vector using FUGENE HD reagent (Roche).
Trp and kyn measurement by high performance liquid
chromatography (HPLC)
Trichloroacetic acid was added to cell culture supernatants
(162.8 µl, 72% to 1 ml of supernatant) for protein precipita-
tion. Trp and Kyn concentrations were measured on a Dionex
Ultimate® 3000 uHPLC (Thermo Fisher Scientific).
Chromatographic separation was achieved on a reversed
phase Accucore™ aQ column (2.6 µm, Thermo Scientific)
with a gradient mobile phase (see Table S1) consisting of
0.1% trifluoroacetic acid (TFA) in water (A) and 0.1% TFA
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in acetonitrile (B). Trp and Kyn peaks were identified based
on comparison to standards, their retention time and UV
emission spectra at 280 nm (Trp) and 365 nm (Kyn).
Results were analyzed using the Chromeleon™ 7.2
Chromatography Data System (Thermo Scientific).
Modulation of Trp levels
An overview of the modulation of Trp levels is provided in
Fig. S3. For Trp starvation experiments, cells were cultured in
custom-made medium without Trp (Thermo Fisher Scientific)
supplemented with dialyzed FCS (Thermo Fisher Scientific).
For the control medium, 78 µM Trp, which represents the Trp
concentration present in regular DMEM, was added to the Trp-
free medium. For Trp supplementation experiments, additional
78 µM of Trp were added to the control medium on day 3 of
cultivation.
Generation of wt and Gcn2 -/- mefs
C57BL/6J wt mice were purchased from Charles River
(Wilmington, MA, USA). Gcn2-/- (B6.129S6-Eif2ak4tm1.2Dron/
J) mice were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA). Following uterus dissection, 14.5 days old embryos
were isolated and washed in PBS. The embryos were mechanically
minced, and subsequently digested enzymatically using 0.25%
Trypsin/EDTA for 5 minutes at 37°C. Tissue suspensions were
homogenized by serially passing them through 18G, 23G and 25G
needles. Single cells were cultured in complete DMEM until
passage 5.
Real-time analysis of cell proliferation
Cell proliferation was monitored in real-time using the
xCelligence RTCA system (Acea Bioscience, Inc.). Wt and
Gcn2 -/- MEFs were seeded in duplicates at a total of 3.000
cells per chamber. Proliferation was measured at 30 minutes
intervals for 4 days as a relative change in electrical impe-
dance. The dimensionless cell index was derived from the
relative change in electrical impedance between the cell free
medium containing well and the impedance measured at each
monitoring time point thereafter. Growth curves are depicted
in the RTCA software as changes in the cell index over time.
Proliferation rates for each of the treatments were determined
by comparison of the slopes of these growth curves using the
RTCA software 1.2.
Modeling of Trp metabolism
To calculate flux changes between U87-MG cells under Trp
sufficiency or deprivation, we extended the previously
published33 mathematical model of Trp metabolism to
include the amino acid transporter SLC1A5. As kinetic con-
stants for this transporter are not available, we used the
constants previously integrated for SLC7A5. Microarray data
of U87-MG cultivated in Trp-free or Trp-containing medium
for 24 h were integrated into the model using SBMLmod as
described previously53. For the microarray U87-MG cells were
cultivated in Trp-free or Trp-containing medium for 24 h,
harvested and RNA was isolated using the RNeasy Mint Kit
(Qiagen). The RNA was biotin-labeled and hybridized to an
Illumina human whole genome Sentrix HumanRef-8
ExpressionBeadChip (Illumina) following the manufacturer’s
protocol. Microarrays were scanned on a beadstation array
scanner and the raw data extracted using the beadarray R
package from bioconductor.org. Bead outliers were removed
if their expression value dropped below a threshold defined by
the imaging system background, non-specific binding and
cross hybridization signal. Individual bead types were flagged
based on bead replicate count. Data were globally normalized
using the Bioconductor lumi package54.
A concentration of 5 µM free Trp corresponding to the
medium blood concentration of free Trp was assumed for the
calculation of steady state fluxes to resemble physiological
conditions.
Statistical analyses
Statistical analyses were performed using GraphPad Prism
version 5.00 (GraphPad Software Inc.) or SigmaPlot 13
(Systat Software GmbH). Correlation analyses were based on
Spearman’s rank analysis. Two-tailed Student’s t-tests were
used for single comparisons. Where applicable, rank sum
analysis by Mann-Whitney U and one-way ANOVA were
conducted. All data are expressed as mean ± s.e.m.
Statistical significance is assumed at P < 0.05 (*P < 0.05,
**P < 0.01, ***P <0.001).
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